Alexander Abigail J, Wilcox Hannah, Horns Joshua John, Wallace Marshall W, Das Rupam, Russell Katie W, Ibele Anna R
Division of General Surgery, University of Utah, 50 Medical Drive N, Salt Lake City, Utah, 84132, USA.
Division of Pediatric Surgery, Primary Children's Hospital, University of Utah, Salt Lake City, Utah, USA.
Surg Endosc. 2025 Aug;39(8):5214-5219. doi: 10.1007/s00464-025-11920-0. Epub 2025 Jun 26.
The burden of obesity-related metabolic dysfunction in adolescents is skyrocketing; the purpose of this study is to understand the impact of adolescent bariatric surgery on the utilization and cost of medications for treatment of metabolic dysregulation.
Using the MarketScan database of commercial health insurance claims from 2011-2019, bariatric surgery patients ages 14-18 (n = 992) were assessed for patterns of medication utilization pre-surgery (beginning of MarketScan enrollment to 6 months before surgery) and post-surgery (> 12 months after surgery). We examined the cost and rate of prescription fills for diabetes, cardiovascular, and dyslipidemia medications. We calculated standardized utilization rates and ran generalized estimating equations for utilization and cost of each medication with Poisson distribution to test for differences at the various time intervals. We also compared utilization and cost for the surgical patients two three control groups, stratified based on body mass index.
Utilization of diabetes and dyslipidemia medications showed a significant decrease in the incidence rate ratio (95% confidence interval) for the post-surgery period relative to the pre-surgery period (0.428 (0.223-0.82) p = 0.01; 0.194 (0.056-0.667) p < 0.01). The total annual cost for the entire cohort of bariatric surgery patients (95% confidence interval) also decreased after surgery with dyslipidemia medications decreasing by $8,666.11 ($1011.84-$16,308.48), cardiovascular medications decreasing by $33,890.68 ($14,403.84-$53,389.44) and diabetes medications decreasing by $45,949.44 ($3,083.14-$94,993.92).
Following adolescent bariatric surgery, there is a decrease in utilization of diabetes and dyslipidemia medications. There was decreased cost for diabetes, dyslipidemia, and cardiovascular medications. These results suggest that performing bariatric surgery during late adolescence is associated with overall improvements in metabolic health.
青少年肥胖相关代谢功能障碍的负担正在急剧上升;本研究的目的是了解青少年减肥手术对治疗代谢失调药物的使用和成本的影响。
利用2011 - 2019年商业健康保险理赔的MarketScan数据库,对14 - 18岁的减肥手术患者(n = 992)在手术前(从MarketScan登记开始到手术前6个月)和手术后(手术后> 12个月)的药物使用模式进行评估。我们检查了糖尿病、心血管疾病和血脂异常药物的成本和处方配药率。我们计算了标准化使用率,并使用泊松分布对每种药物的使用和成本进行广义估计方程分析,以测试不同时间间隔的差异。我们还比较了手术患者与两个对照组(根据体重指数分层)的使用情况和成本。
与手术前相比,手术后糖尿病和血脂异常药物的使用率在发病率比值(95%置信区间)上显著降低(0.428(0.223 - 0.82)p = 0.01;0.194(0.056 - 0.667)p < 0.01)。减肥手术患者整个队列的年度总成本(95%置信区间)在手术后也有所下降,血脂异常药物下降了8,666.11美元(1,011.84 - 16,308.48美元),心血管药物下降了33,890.68美元(14,403.84 - 53,389.44美元),糖尿病药物下降了45,949.44美元(3,083.14 - 94,993.92美元)。
青少年减肥手术后,糖尿病和血脂异常药物的使用减少。糖尿病、血脂异常和心血管药物的成本降低。这些结果表明,在青春期后期进行减肥手术与代谢健康的总体改善有关。